About: Ranolazine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ranolazine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia] (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B63D1-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B63D2-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Hale SL, Kloner RA: Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J Cardiovasc Pharmacol Ther. 2006 Dec;11(4):249-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17220471 # Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006 Dec;41(6):1031-8. Epub 2006 Oct 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17027025 # Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. Epub 2006 Jun 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16875985 # Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):309-16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14734593 # Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297(16):1775-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17456819 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	7 hours (en)
http://linked.open...ugbank/indication	For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates. (en)
http://linked.open...bank/manufacturer	Mikart Inc.
sameAs	Ranolazine Ranolazine
Title	Ranolazine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/chemspider/51354 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/drugbank/DB00243 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/national-drug-code-directory/61958-1001-1 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/pubchem-compound/56959 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/pubchem-substance/46505145 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/pharmgkb/PA164746007 http://linked.opendata.cz/resource/drugbank/drug/DB00243/identifier/wikipedia/Ranolazine
http://linked.open...mechanismOfAction	The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia. (en)
http://linked.open...drugbank/packager	American therapeutics inc DSM Corp. Gilead Sciences Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6303607
http://linked.open...outeOfElimination	Ranolazine is metabolized rapidly and extensively in the liver and intestine; less than 5% is excreted unchanged in urine and feces. (en)
http://linked.open.../drugbank/synonym	Ranexa (en)
http://linked.open...drugbank/toxicity	In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop. (en)
http://linked.open...k/foodInteraction	Take without regard to meals. (en) Grapefruit and grapefruit juice should be avoided throughout treatment. (en)
http://linked.open...nk/proteinBinding	62% (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Raghupathi Reddy Anumula, Goverdhan Gilla, Sampath Aalla, Lokeswara Rao Madivada, Prabhaker Macherla, Srinivas Kurella, Kavitha Charagondla, Ramamurthy Kasula, Rajagopala Rao Mandadapu, Krishaniah Charagondla, Malati Vakamulla, Durga Prasad Janaki Bhavanipurapu, "PREPARATION OF RANOLAZINE." U.S. Patent US20110151258, issued June 23, 2011. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0156295
foaf:page	http://www.drugs.com/cdi/ranolazine.html http://www.rxlist.com/cgi/generic/ranexa.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B63D7-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B63DD-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B63DC-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B63D9-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B63DA-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B63DB-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B63D5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B63ED-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B63D3-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B63D6-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B63EE-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B63D4-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Ranolazine
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B63E3-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B63E4-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B63DE-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B63DF-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B63E1-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B63E0-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B63E2-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	142387-99-3 (en)
http://linked.open...gbank/containedIn	Maprotiline HCl 75 mg tablet Novo-Maprotiline 75 mg Tablet Halotin 1% cream Maprotiline 25 mg tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B63E9-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B63EB-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B63EC-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B63E8-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B63E7-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B63EA-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B63D8-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B63E5-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B63E6-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 116 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software